SS-31 (Elamipretide)

Fat LossMitochondria-targeted tetrapeptide (elamipretide)Established

Same active peptide as elamipretide. Forzinity received FDA accelerated approval in 2025 for Barth syndrome (≥30 kg). Research SS-31 vials are not the approved product.

Calculate Dose

For research use only.

Key Facts

CAS: 736992-21-5
Molecular Weight (MW): 639.8 g/mol
Half-life: ~1-2 hours
Unit: mg
Administration Route: Subcutaneous
Frequency: Daily
Last updated: 8/23/2026
Targets: Cardiolipin

Overview

Same active peptide as elamipretide. Forzinity received FDA accelerated approval in 2025 for Barth syndrome (≥30 kg). Research SS-31 vials are not the approved product.